Ciphergen, UTMB Pen Liver Disease Biomarker Alliance; Shares Continue to Fall in Wake of Revenue Investigation | GenomeWeb

NEW YORK , Nov. 21 (GenomeWeb News) - Ciphergen and the University of Texas Medical Branch at Galveston plan to discover, validate, and characterize new liver disease biomarkers, the company said today.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.